Total Payments
$15,515
2024 Payments
$457.28
Companies
8
Transactions
36
Medicare Patients
597
Medicare Billing
$94,928
Payment Breakdown by Category
Consulting$9,929 (64.0%)
Research$2,939 (18.9%)
Travel$1,333 (8.6%)
Food & Beverage$1,314 (8.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $9,929 | 3 | 64.0% |
| Unspecified | $2,939 | 16 | 18.9% |
| Travel and Lodging | $1,333 | 3 | 8.6% |
| Food and Beverage | $1,314 | 14 | 8.5% |
Payments by Type
General
$12,576
20 transactions
Research
$2,939
16 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| GlaxoSmithKline, LLC. | $12,231 | 21 | $0 (2019) |
| Eli Lilly and Company | $1,699 | 4 | $0 (2019) |
| Novartis Pharmaceuticals Corporation | $990.18 | 5 | $0 (2018) |
| Inari Medical, Inc. | $232.63 | 1 | $0 (2024) |
| Balt USA, LLC | $209.24 | 2 | $0 (2024) |
| Janssen Scientific Affairs, LLC | $119.25 | 1 | $0 (2018) |
| Amgen Inc. | $17.91 | 1 | $0 (2019) |
| Abbott Laboratories | $15.41 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $457.28 | 4 | Inari Medical, Inc. ($232.63) |
| 2019 | $9,366 | 21 | GlaxoSmithKline, LLC. ($9,224) |
| 2018 | $4,292 | 8 | GlaxoSmithKline, LLC. ($3,007) |
| 2017 | $1,400 | 3 | Eli Lilly and Company ($1,275) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 08/14/2024 | Balt USA, LLC | Prestige Coil System (Device) | Food and Beverage | In-kind items and services | $21.85 | General |
| Category: Neurology | ||||||
| 06/19/2024 | Balt USA, LLC | Prestige Coil System (Device) | Food and Beverage | In-kind items and services | $187.39 | General |
| Category: Neurology | ||||||
| 06/03/2024 | Abbott Laboratories | PERCLOSE PROGLIDE (Device) | Food and Beverage | In-kind items and services | $15.41 | General |
| Category: Vascular | ||||||
| 04/12/2024 | Inari Medical, Inc. | FLOWTRIEVER CATHETER, S (Device), CT THROMBECTOMY SYSTEM KIT | Food and Beverage | In-kind items and services | $232.63 | General |
| Category: VTE | ||||||
| 10/31/2019 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $37.90 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/31/2019 | GlaxoSmithKline, LLC. | — | — | Cash or cash equivalent | $19.65 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $267.00 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $206.81 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $167.63 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $149.13 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $127.95 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $89.05 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $82.65 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $50.17 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $23.22 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 10/10/2019 | GlaxoSmithKline, LLC. | — | — | In-kind items and services | $18.60 | Research |
| Study: MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | ||||||
| 09/27/2019 | Amgen Inc. | MVASI (Biological), Neulasta, Vectibix | Food and Beverage | In-kind items and services | $17.91 | General |
| Category: Oncology | ||||||
| 04/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $5,292.54 | General |
| 03/15/2019 | GlaxoSmithKline, LLC. | — | Travel and Lodging | In-kind items and services | $221.50 | General |
| 03/15/2019 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $147.21 | General |
| 03/15/2019 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $105.98 | General |
| 03/15/2019 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $99.42 | General |
| 03/15/2019 | GlaxoSmithKline, LLC. | — | Food and Beverage | In-kind items and services | $80.78 | General |
| 03/11/2019 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $2,036.90 | General |
| 02/25/2019 | Eli Lilly and Company | — | — | Cash or cash equivalent | $124.00 | Research |
| Study: A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF DOXORUBICIN PLUS OLARATUMAB VERSUS DOXORUBICIN PLUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 3 TRIAL OF DOXORUBICIN PLUS OLARATUMAB VERSUS DOXORUBICIN PLUS PLACEBO IN PATIENTS WITH ADVANCED OR METASTATIC SOFT TISSUE SARCOMA | Eli Lilly and Company | $1,324 | 3 |
| MASTER PROTOCOL TO ASSESS THE SAFETY AND ANTITUMOR ACTIVITY OF GENETIC | GlaxoSmithKline, LLC. | $1,240 | 12 |
| A PHASE 2 STUDY OF ONCE-WEEKLY LY3298176 COMPARED WITH PLACEBO AND DULAGLUTIDE IN PATIENTS WITH TYPE 2 DIABETES MELLITUS | Eli Lilly and Company | $375.00 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 182 | 386 | $171,253 | $32,627 |
| 2022 | 2 | 41 | 85 | $42,789 | $8,175 |
| 2021 | 6 | 165 | 317 | $88,088 | $25,890 |
| 2020 | 6 | 209 | 394 | $113,190 | $28,235 |
Total Patients
597
Total Services
1,182
Medicare Billing
$94,928
Procedure Codes
19
All Medicare Procedures & Services
19 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 90 | 277 | $119,110 | $22,660 | 19.0% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 36 | 36 | $28,692 | $5,586 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 32 | 41 | $11,931 | $2,265 | 19.0% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 11 | 16 | $9,040 | $1,666 | 18.4% |
| 99441 | Telephone medical discussion with physician, 5-10 minutes | Facility | 2023 | 13 | 16 | $2,480 | $450.45 | 18.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 24 | 68 | $29,240 | $5,620 | 19.2% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 17 | 17 | $13,549 | $2,555 | 18.9% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 163 | $42,076 | $13,352 | 31.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 27 | 39 | $15,579 | $4,570 | 29.3% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 20 | 54 | $12,374 | $3,351 | 27.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 19 | 19 | $11,303 | $2,917 | 25.8% |
| 99231 | Subsequent hospital inpatient care, typically 15 minutes per day | Facility | 2021 | 13 | 26 | $3,960 | $860.86 | 21.7% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 11 | 16 | $2,796 | $839.38 | 30.0% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 94 | 245 | $62,720 | $15,709 | 25.0% |
| 99215 | Established patient office or other outpatient, visit typically 40 minutes | Facility | 2020 | 31 | 59 | $22,420 | $5,722 | 25.5% |
| 99205 | New patient office or other outpatient visit, typically 60 minutes | Facility | 2020 | 24 | 24 | $13,368 | $3,368 | 25.2% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 17 | 17 | $7,667 | $1,929 | 25.2% |
| 99213 | Established patient office or other outpatient visit, typically 15 minutes | Facility | 2020 | 24 | 25 | $4,175 | $990.01 | 23.7% |
| 99441 | Physician telephone patient service, 5-10 minutes of medical discussion | Facility | 2020 | 19 | 24 | $2,840 | $516.63 | 18.2% |
About Dr. Warren Chow, MD
Dr. Warren Chow, MD is a Internal Medicine healthcare provider based in Orange, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/24/2006. The National Provider Identifier (NPI) number assigned to this provider is 1093822017.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Warren Chow, MD has received a total of $15,515 in payments from pharmaceutical and medical device companies, with $457.28 received in 2024. These payments were reported across 36 transactions from 8 companies. The most common payment nature is "Consulting Fee" ($9,929).
As a Medicare-enrolled provider, Chow has provided services to 597 Medicare beneficiaries, totaling 1,182 services with total Medicare billing of $94,928. Data is available for 4 years (2020–2023), covering 19 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Medical Oncology, Hematology & Oncology
- Location Orange, CA
- Active Since 08/24/2006
- Last Updated 03/25/2025
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1093822017
Products in Payments
- VOTRIENT (Drug) $970.45
- FLOWTRIEVER CATHETER, S (Device) $232.63
- Prestige Coil System (Device) $209.24
- YONDELIS (Drug) $119.25
- MEKINIST (Drug) $19.73
- MVASI (Biological) $17.91
- PERCLOSE PROGLIDE (Device) $15.41
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Orange
Dr. May Cho, M.d, M.D
Internal Medicine — Payments: $335,831
Internal Medicine $335,831
Dr. Elizabeth Brem, Md, MD
Internal Medicine — Payments: $285,872
Internal Medicine $285,872
Dr. Ritesh Parajuli, Md, MD
Internal Medicine — Payments: $180,846
Internal Medicine $180,846
Beth Valashinas, Do, DO
Internal Medicine — Payments: $96,719
Internal Medicine $96,719
Dr. Jennifer Valerin, M.d, M.D
Internal Medicine — Payments: $83,603
Internal Medicine $83,603
Dr. Teferi Mitiku, M.d, M.D
Internal Medicine — Payments: $69,169
Internal Medicine $69,169